The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, ...
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...
Shares in Bristol-Myers Squibb (BMY) surged Friday, after the Food and Drug Administration approved the drugmaker's novel ...
Key Takeaways Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration.The ...
Bristol Myers Squibb stock jumped after the pharma company won approval for its new schizophrenia drug late Thursday. “This ...
Answers Pet Food and Darwin’s Natural Pet Products, were found to have produced pet food that was contaminated with the ...
Pet owners are advised to throw away the at-risk products safely, so pets and children can't access and ingest them ...
The treatment offers hope to thousands of patients who do not respond to existing medications, and has shown promise in treating other neurological disorders.
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in ...
While one brand has withdrawn the affected products, a second, Darwin's Natural Pet Products, has not, according to the FDA.
Sanofi recorded 10.72 billion euros ($11.94 billion) in sales for Dupixent in 2023, which includes Regeneron's share.
The U.S. FDA issued warnings for ANSWERS Pet Food and Darwin's Natural Pet Products as they contain Salmonella and Listeria.